Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (GlobeNewswire) - Mar 5, 2024 - "In 2024 the Company plans to accomplish the following key business objectives: Continue to advance Phase 2 ReSPECT-GBM trial and present data in the second half of 2024; Finalize ReSPECT-GBM pivotal design with FDA."
Clinical protocol • P2 data • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor
|